Intestinal tissue kallikrein-kallistatin profile in inflammatory bowel disease

Author： Stadnicki A. Mazurek U. Plewka D. Wilczok T.

Publisher： Elsevier

ISSN： 1567-5769

Source： International Immunopharmacology, Vol.3, Iss.7, 2003-07, pp. : 939-944

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Expression of epidermal growth factor receptor (EGFR) is frequent in inflammatory bowel disease (IBD)-associated intestinal cancer

By Svrcek Magali Cosnes Jacques Tiret Emmanuel Bennis Malika Parc Yann Fléjou Jean-François

Virchows Archiv, Vol. 450, Iss. 2, 2007-02 ,pp. : 243-244

Springer Publishing Company

Access to resources Recommend Favorite

Medical Management of Inflammatory Bowel Disease in the New Millennium

By Lombardi Daniel A. Feller Edward R. Shah Samir A.

Comprehensive Therapy, Vol. 28, Iss. 1, 2002-03 ,pp. : 39-49

Humana Press, Inc

Access to resources Recommend Favorite

Utility of Screening for Chronic Granulomatous Disease in Patients with Inflammatory Bowel Disease

By Jaggi Preeti

Journal of Clinical Immunology, Vol. 32, Iss. 1, 2012-02 ,pp. : 78-81

Springer Publishing Company

Access to resources Recommend Favorite

The Opioid Antagonist Naltrexone Improves Murine Inflammatory Bowel Disease

By Matters Gail Harms John McGovern Christopher Fitzpatrick Leo Parikh Anuj Nilo Nicholas Smith Jill

Journal of Immunotoxicology, Vol. 5, Iss. 2, 2008-04 ,pp. : 179-187

Informa Healthcare

Access to resources Recommend Favorite

Tacrolimus: a new immunosuppressant for steroid refractory inflammatory bowel disease

By Fellermann K. Herrlinger K.R. Witthoeft T. Homann N. Ludwig D. Stange E.F.

Transplantation Proceedings, Vol. 33, Iss. 3, 2001-05 ,pp. : 2247-2248

Elsevier

Access to resources Recommend Favorite